share_log

Needham Maintains Buy on NextCure, Lowers Price Target to $4

Needham Maintains Buy on NextCure, Lowers Price Target to $4

Needham 維持對NextCure的買入,將目標價下調至4美元
Benzinga ·  2023/12/14 11:30

Needham analyst Gil Blum maintains NextCure (NASDAQ:NXTC) with a Buy and lowers the price target from $6 to $4.

Needham分析師吉爾·布魯姆維持NextCure(納斯達克股票代碼:NXTC)的買入並將目標股價從6美元下調至4美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論